Patent US4532241A successfully refreshed from Google Patents.
US4320118A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Deca-, undeca-, dodeca- and tridecapeptides with thymic activity
Assignee: Syntex USA LLC
•
Filing: 1980-12-22
•
Granted: 1982-03-16
•
Expires: 2000-12-22
Abstract
Abstract Novel peptides of the formula: <IMAGE> wherein: A, A' and A'' are each independently Gly, D-Ala, D-Leu, or D-Trp, wherein A may optionally be N-alkylated or N-acylated; B is Pro, DELTA 3-Pro, Thz, or diMeThz; C and C' are each independently Thr, Ser, Val, or alloThr; D is Glu, Gln, Asp, or Asn; R is hydrogen, or is lower alkyl or lower acyl, substituted for one of the hydrogens on the epsilon -amino group of the lysyl residue; X is Cys, Ala, ABU, or Cys(Me); and Y is selected from the group consisting of hydroxy, Pro, Pro-Leu, and Pro-Leu-Met, -NH2, ProNH2, Pro-LeuNH2 and Pro-leu-MetNH2; and the pharmaceutically acceptable salts thereof, are useful for increasing immunologic competence. Methods for preparation of the peptides are also described.
Inventors
- 👤 Abraham White, deceased
- 👤 John J. Nestor
- 👤 Gordon H. Jones
- 👤 Pamela M. Burton
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 03:24
CPC Classifications
C; C07; C07K; C07K1/00; C07K14/00; C07K14/435; C07K14/575; C07K14/655; C07K14/6555; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/18
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
116 words
A peptide of the formula: ##STR10## and the pharmaceutically acceptable salts thereof, wherein: A, A' and A" are each independently Gly, D-Ala, D-Leu, or D-Trp; wherein A may optionally be N-alkylated or N-acylated; B is Pro, α 3 -Pro, Thz, or diMeThz; C and C' are each independently Thr, Ser, Val, or alloThr; D is Glu, Gln, Asp, or Asn; R is hydrogen, or lower alkyl or lower acyl, substituted for one of the hydrogens on the ε-amino group of the lysyl residue; X is Cys, Ala, ABU, or Cys(Me); and Y is selected from the group consisting of hydroxy, Pro, Pro-Leu, and Pro-Leu-Met; -NH 2 , ProNH 2 , Pro-LeuNH 2 and Pro-leu-Met-NH 2 .
Claim 2
Dependent Claim
116 words
A peptide of the formula: ##STR10## and the pharmaceutically acceptable salts thereof, wherein: A, A' and A" are each independently Gly, D-Ala, D-Leu, or D-Trp; wherein A may optionally be N-alkylated or N-acylated; B is Pro, α 3 -Pro, Thz, or diMeThz; C and C' are each independently Thr, Ser, Val, or alloThr; D is Glu, Gln, Asp, or Asn; R is hydrogen, or lower alkyl or lower acyl, substituted for one of the hydrogens on the ε-amino group of the lysyl residue; X is Cys, Ala, ABU, or Cys(Me); and Y is selected from the group consisting of hydroxy, Pro, Pro-Leu, and Pro-Leu-Met; -NH 2 , ProNH 2 , Pro-LeuNH 2 and Pro-leu-Met-NH 2 .
Claim 3
Dependent Claim
50 words
The peptide of claim 1, and the pharmaceutically acceptable salts thereof, wherein: A, A', and A" are each independently Gly, D-ala, D-Leu or D-Trp, wherein A may optionally be N-acylated or N-alkylated; B is Pro; C and C' are Thr; R is hydrogen; and X is Ala, Cys, or Cys(Me).
Claim 4
Dependent Claim
41 words
The peptide of claim 2, and the pharmaceutically acceptable salts thereof, wherein: A, A' and A" are each independently Gly or D-Ala, wherein A may optionally be N-acylated or N-alkylated; D is Glu or Gln, and X is Ala or Cys.
Claim 5
Dependent Claim
29 words
The peptide of claim 1 and the pharmaceutically acceptable salts thereof, wherein Y is selected from the group consisting of hydroxy, Pro, --NH 2 , and ProNH 2 .
Claim 6
Dependent Claim
50 words
The peptide of claim 4, and the pharmaceutically acceptable salts thereof, wherein: A, A', and A" are each independently Gly, D-ala, D-Leu or D-Trp; wherein A may optionally be N-acylated or N-alkylated; B is Pro; C and C' are Thr; R is hydrogen; and X is Ala, Cys, or (Cys(Me).
Claim 7
Dependent Claim
41 words
The peptide of claim 5, and the pharmaceutically acceptable salts thereof, wherein: A, A' and A" are each independently Gly or D-Ala wherein A may optionally be N-acylated or N-alkylated; D is Glu or Gln; and X is Ala or Cys.
Claim 8
Dependent Claim
29 words
The peptide of claim 5 or a pharmaceutically acceptable salt wherein A, A' and A" are Gly, D is Glu, X is Cys(Me) and Y is OH, i.e. Gly-Pro-Thr-Gly-Thr-Gly-Glu-Ser-Lys-Cys(Me).
Claim 9
Dependent Claim
30 words
The peptide of claim 6 or a pharmaceutically acceptable salt thereof wherein A, A' and A" are Gly, D is Glu, X is Ala and Y is OH, i.e. Gly-Pro-Thr-Gly-Thr-Gly-Glu-Ser-Lys-Ala.
Claim 10
Dependent Claim
30 words
The peptide of claim 6 or a pharmaceutically acceptable salt thereof, wherein A, A' and A" are Gly, D is Glu, X is Cys and Y is OH, i.e. Gly-Pro-Thr-Gly-Thr-Gly-Glu-Ser-Lys-Cys.
Claim 11
Dependent Claim
32 words
The peptide of claim 6 or a pharmaceutically acceptable salt thereof, wherein A and A' are Gly, A" is D-Ala, D is Glu, X is Ala and Y is OH, i.e. Gly-Pro-Thr-Gly-Thr-D-Ala-Glu-Ser-Lys-Ala.
Claim 12
Dependent Claim
30 words
The peptide of claim 6 or a pharmaceutically acceptable salt thereof, wherein A, A' and A" are Gly, D is Glu, X is Cys and Y is Pro, i.e. Gly-Pro-Thr-Gly-Thr-Gly-Glu-Ser-Lys-Cys-Pro.
Claim 13
Dependent Claim
32 words
The peptide of claim 6 or a pharmaceutically acceptable salt thereof, wherein A and A" are Gly, A' is D-Ala, D is Glu, X is Ala, and Y is OH, i.e. Gly-Pro-Thr-D-Ala-Thr-Gly-Glu-Ser-Lys-Ala.
Claim 14
Dependent Claim
33 words
A pharmaceutical composition useful for increasing immunologic competence, comprising a therapeutically effective amount of the peptide of claim 1 or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable, non-toxic carrier.
Claim 15
Dependent Claim
44 words
A method of increasing immunologic competence in mammals which comprises administering to a subject in need of such treatment, a therapeutically effective amount of, or a pharmaceutical composition containing an effective amount of, the peptide of claim 1 or a pharmaceutically acceptable salt thereof.
Claim 16
Dependent Claim
27 words
The peptide of claim 5 or the pharmaceutically acceptable salts thereof; wherein A, A', and A" are Gly, X is Cys(Me), and Y is Pro, i.e. Gly-Pro-Thr-Gly-Thr-Gly-Glu-Ser-Lys-Cys(Me)-Pro.
References Cited (Backward Citations)
US4046877A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-03-15 | 1985-09-14 | 1986-03-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-03-15 | 1989-09-14 | 1990-03-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-03-15 | 1993-09-14 | 1994-03-16 | $7700.00 | Window Closed / Lapsed |